Skip to main content
Submitted by sobecksm on

Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer. Which patients will benefit the most, however, remains unclear; current biomarkers such as PD-L1 that are used to predict response are mediocre at best.

https://news.vumc.org/2023/12/15/clinical-trial-shows-efficacy-for-atezolizumab-combined-with-carboplatin/
Tom Wilemon
Locked